These trichomes are tiny, hair-like crystals that cover the leaves and buds of the cannabis plant. Trichomes product the hundreds of known cannabinoids that can be found in cannabis. Of the 100+ cannabinoids that have been identified in the cannabis species, CBD and THC have been studied the most extensively for their role in the endocannabinoid system.
There is a strong sedative quality to CBD hemp oil, making it a popular remedy for people with insomnia, sleeplessness, interrupted sleep, post-traumatic stress disorder, restless leg disorder, and other night-time issues. Dr. Scott Shannon, Assistant Clinical Professor of Psychiatry at the University of Colorado School of Medicine, USA, published a report in the Permanete Journal, in which he recommended either inhaling a small amount of CBD oil, applying it to one’s chest, or even putting a few drops on one’s pillow to help get a good night’s sleep.
People who experience psychosis may produce too much or even too little cannabinoids (from overactive dopamine receptors). CBD is milder than our internal cannabinoids and helps to re-establish a balance of cannabinoids in the brain. CBD also helps lower inflammation, which is often increased in schizophrenia. THC, on the other hand, is stronger than our internal cannabinoids (anandamide and 2-AG), this way potentially triggering psychosis [46, 48].
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
THC does typically come with a long list of health benefits, but the clinical use of this cannabis compound is often limited by its unwanted psychoactive side effects in people. For this reason, interest in non-intoxicating phytocannabinoids, such as CBD, has substantially increased in recent years. In fact, CBD is being used in conjunction with THC for more favorable effects.
Other targets for CBD include transient receptor potential (TRP) channels that are involved with the modulation of intracellular calcium (1, 6). Cannabinoids are highly lipophilic, allowing access to intracellular sites of action, resulting in increases in calcium in a variety of cell types including hippocampal neurons. CBD actions on calcium homeostasis may provide a basis for CBD neuroprotective properties.
Pharmacology published a study in 2016 looking at medical marijuana for migraines, specifically in relation to its effects on serotonin, with very positive results. You’ll notice that neither study looked at CBD in isolation from other cannabinoids (which is an issue with a lot of research on CBD and pain). Truthfully, the research on CBD alone just isn’t sufficient to make any pronouncements about its effects on headache pain.
I use this for my anxiety and for my arthritis. The topical works great for my chronic neck pain. The best way to go is to get your own raw, tested material and use it in whatever form you like. It’s quite easy to make your own extract. This has worked better for me, rather than relying on a purchased, untested product – where some seem to work and others are a waste. But even with those that work, of course the cost is ridiculous and not affordable, thanks to all these corporate-pleasing laws in place, not there for the people – don’t delude yourselves.